Evaluation of ABSOLVE in Diabetic Foot Ulcers

Diabetic Foot Ulcers Clinical Trial

— ABSOLVE  

Official title:

A Prospective Randomized Controlled Blinded Study to Evaluate the Safety and Efficacy of rhPDGF-BB Saturated Collagen Wound Dressings on Diabetic Foot Ulcers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03037970
• Other study ID #: Lynch 02-01
• Status: Recruiting
• Phase: Phase 2
• First received: January 26, 2017
• Last updated: January 30, 2017
• Start date: January 30, 2017
• Est. completion date: October 15, 2017

Study information

• Verified date: January 2017
• Source: Lynch Biologics LLC
• Contact: Sam Lynch, DMSc, DMD
• Phone: 615-218-1624
• Email: sam.lynch[@]lynchbiologics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ABSOLVE Biologic Wound Matrix is a combination of recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a bovine type I collagen wound dressing matrix. ABSOLVE is under development for the treatment of chronic and acute wounds. This study investigates the safety and efficacy of ABSOLVE in chronic diabetic foot ulcers (DFUs).

Description:

Patients with diabetes are at risk for developing serious health problems that may affect the feet, eyes, kidneys, skin and heart. Foot ulcerations are of great significance to the lives of millions of diabetic patients, representing one of the most common and serious complications in these patients. Up to 25% of diabetics will develop a diabetic foot ulcer (DFU) at some point in their lifetime. The prevalence of DFUs among diabetics is 4% to 10%. More than half of all foot ulcers will become infected requiring hospitalization and 1 in 5 will require amputation. Foot ulcers account for 85,000 non-trauma related lower limb amputations annually in the USA. Every 20 seconds, somewhere in the world, a limb is lost as a consequence of diabetes. Moreover, 85% of leg amputations are preceded by DFUs and more than 60% of non-traumatic lower extremity amputations (LEA) performed in the United States each year occurs secondary to complications of diabetes mellitus. After a major amputation, 50% of patients will have another limb amputated within two years. Mortality rates subsequent to amputation are alarmingly high - up to 40% at 1 year and 80% at 5 years. Patients with a history of a DFU have a 40% greater mortality rate compared to patients with diabetes alone. Improved treatments for DFUs are clearly a matter of great significance.

In this study, the investigation will be focused on the safety and efficacy of ABSOLVE in treating diabetic foot ulcers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: October 15, 2017
• Est. primary completion date: August 15, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adults 30 to 75 years of age

• A diagnosis of Type 1 or 2 diabetes with HbAlc between 6 and 12%, an adequate blood supply defined as TcpO2 > 30 mmHg or an ankle brachial index (ABI) = 0.7 on the foot with the target ulcer

• A DFU 2 cm2-14 cm2 that extends into the subcutaneous tissues or beyond (=Wagner Grade 2)

• A DFU of at least 6 weeks duration and under care of the study investigator for at least 2 weeks following standard wound debridement with less than 30% healing

• Body Mass Index (BMI) of 18.5 to 40 kg/m2

• Co-morbidities are under control and non-life threatening as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests

• A negative pregnancy test at Screening

• Both males and WCBP agree to use acceptable contraceptive methods while on study

• Able to comprehend and sign an ICF.

Exclusion Criteria:

• Evidence of clinically significant findings on screening evaluations (clinical, laboratory, and ECG) which, in the opinion of the Investigator would pose a safety risk or interfere with interpretation of safety data

• Current or recent history of significant bacterial, fungal, viral, or mycobacterial infection

• History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin

• History of myocardial infarction, congestive heart failure, or stroke

• History of psychotic disorder

• History of alcoholism or drug addiction

• Positive drug screen at Screening

• Current treatment or treatment within 30 days prior to first dose of study products with another investigational drug or current enrollment in another clinical trial

• Known history of HIV, hepatitis B, or hepatitis C

• Known hypersensitivity to any of the product's components

• Subjects who are unable or unlikely to comply with the protocol

• Pregnant or lactating.

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcers
• Foot Ulcer
• Ulcer

Intervention

Drug:
• RhPDGF-BB
One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.

Other:
• Placebo
Collagen Wound Dressing wetted with buffer.

Locations

Country	Name	City	State
Guatemala	Centro Medico Militar	Guatemala City

Sponsors (3)

Lead Sponsor	Collaborator
Lynch Biologics LLC	Centro Medico Militar, Medelis Inc.

Country where clinical trial is conducted

Guatemala, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)	Determine safety and tolerability of ABSOLVE on patients having a poorly healing diabetic foot ulcer.	Week 0 - 24
Primary	Successful wound healing for at least two consecutive measurements. (Efficacy)	Successfully healed wound must remain closed for at least two consecutive measurements, one of which will be at the 12-week examination.	Week 12
Secondary	Wound Size	The percent change in wound size (closure) over time.	Week 0 - 24
Secondary	Wound Closure	Percent incidence of complete wound closure over time.	Week 0 - 24
Secondary	Complication rate	Reduction in complications.	Week 0 - 24